Neuburgh Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

Neuburgh Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$11.6M	Buy	68,176 +20,912	+44%	+$3.7M	0.36%	59
2019 Q2	$8.67M	Sell	47,264 -4,144	-8%	-$724K	0.28%	77
2019 Q1	$9.46M	Buy	51,408 +976	+2%	+$180K	0.32%	70
2018 Q4	$8.36M	Sell	50,432 -2,112	-4%	-$366K	0.33%	68
2018 Q3	$10.1M	Sell	52,544 -3,184	-6%	-$567K	0.33%	67
2018 Q2	$9.47M	Sell	55,728 -496	-0.9%	-$76.9K	0.32%	69
2018 Q1	$9.16M	Buy	56,224 +25,680	+84%	+$4.19M	0.32%	67
2017 Q4	$4.58M	Sell	30,544 -848	-3%	-$126K	0.16%	115
2017 Q3	$4.77M	Sell	31,392 -10,992	-26%	-$1.65M	0.18%	111
2017 Q2	$5.46M	Sell	42,384 -1,760	-4%	-$212K	0.21%	97
2017 Q1	$4.83M	Sell	44,144 -4,368	-9%	-$385K	0.19%	104
2016 Q4	$3.57M	Buy	+48,512	New	+$3.95M	0.16%	112

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Neuburgh Advisers's VRTX Position: Q3 2019 in Review

Neuburgh Advisers increased its Vertex Pharmaceuticals (VRTX) stake by 44% in Q3 2019, buying an estimated $3.7M and bringing the position to 68,176 shares worth $11.6M. The position accounts for 0.36% of the portfolio, ranked #59.

Neuburgh Advisers first reported a position in VRTX in Q4 2016 and has held it in 12 quarters since. 707 funds tracked by Wall St. Rank hold VRTX as of Q3 2019.

Neuburgh Advisers held 68,176 shares of Vertex Pharmaceuticals worth $11.6M as of Q3 2019.
Neuburgh Advisers bought 20,912 Vertex Pharmaceuticals shares in Q3 2019, an estimated $3.7M.
Vertex Pharmaceuticals made up 0.36% of Neuburgh Advisers's portfolio in Q3 2019, its #59 holding.
Neuburgh Advisers first reported a position in Vertex Pharmaceuticals in Q4 2016 and has held it in 12 quarters since.
707 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.